01 4. (Twice amended) The method of claim 1 wherein the recombinant adenovirus vector consists of a polynucleotide having a sequence set forth in SEQ ID NO:5.

02 7. (Thrice amended) The method of claim 4 wherein the cell is a cell to be transplanted into a patient.

03 10. (Four times amended) A method for decreasing the rejection of transplanted cells comprising contacting the cells ex vivo with a recombinant adenovirus comprising a polynucleotide encoding a RIDα-S polypeptide, a RIDα-L polypeptide and a RIDβ polypeptide, as disclosed in SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:4, wherein (a) the polynucleotide is operably linked to a cytomegalovirus ("CMV") promoter, (b) the adenovirus enters the cell and delivers the polynucleotide to the cell, (c) the RIDα-S polypeptide, RIDα-L polypeptide and RIDβ polypeptide are expressed in the cell in an amount sufficient to inhibit apoptosis of the cell, (d) the cell expresses Fas, DR3, TRAIL-R1, or TRAIL-R2, (e) the adenovirus lacks at least one functional E1 gene and (f) the rejection is mediated by Fas receptor activity.

04 13. (Twice amended) The method of claim 10 wherein the recombinant adenovirus vector consists of a polynucleotide having a sequence set forth in SEQ ID NO:5.

05 26. (New) The method of claim 13 wherein the transplanted cells are in a mouse.